STOCK TITAN

Immunocore Holdings plc American Depositary Shares - IMCR STOCK NEWS

Welcome to our dedicated news page for Immunocore Holdings plc American Depositary Shares (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings plc American Depositary Shares.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunocore Holdings plc American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunocore Holdings plc American Depositary Shares's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
conferences
-
Immunocore Holdings plc American Depositary Shares

Nasdaq:IMCR

IMCR Rankings

IMCR Stock Data

2.91B
32.22M
4.45%
82.24%
9.26%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
OXFORDSHIRE

About IMCR

immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body’s own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host’s own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes.